Serge K. Lyashchenko

4.5k total citations
73 papers, 2.6k citations indexed

About

Serge K. Lyashchenko is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Serge K. Lyashchenko has authored 73 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Radiology, Nuclear Medicine and Imaging, 29 papers in Oncology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Serge K. Lyashchenko's work include Radiopharmaceutical Chemistry and Applications (45 papers), Medical Imaging Techniques and Applications (17 papers) and Glioma Diagnosis and Treatment (12 papers). Serge K. Lyashchenko is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (45 papers), Medical Imaging Techniques and Applications (17 papers) and Glioma Diagnosis and Treatment (12 papers). Serge K. Lyashchenko collaborates with scholars based in United States, Germany and Canada. Serge K. Lyashchenko's co-authors include Jason S. Lewis, Jorge A. Carrasquillo, Neeta Pandit‐Taskar, Gary A. Ulaner, Joseph A. O’Donoghue, Steven M. Larson, Pat Zanzonico, Wolfgang Weber, Shutian Ruan and David M. Hyman and has published in prestigious journals such as Journal of Clinical Oncology, Cell Metabolism and Cancer Research.

In The Last Decade

Serge K. Lyashchenko

71 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Serge K. Lyashchenko United States	28	1.5k	1.1k	530	513	454	73	2.6k
Ganesan Vaidyanathan United States	37	2.6k 1.8×	1.1k 1.0×	1.0k 1.9×	702 1.4×	350 0.8×	128	3.9k
Sean Carlin United States	36	1.9k 1.3×	741 0.7×	1.1k 2.1×	659 1.3×	969 2.1×	100	3.7k
Hanwen Zhang United States	28	1.7k 1.1×	1.2k 1.1×	668 1.3×	519 1.0×	437 1.0×	64	3.6k
Joseph A. O’Donoghue United States	41	2.9k 2.0×	1.2k 1.1×	766 1.4×	1.3k 2.6×	965 2.1×	129	4.4k
Richard A. Messmann United States	21	1.3k 0.9×	1.2k 1.2×	976 1.8×	1.4k 2.7×	362 0.8×	49	3.2k
Steve Y. Cho United States	27	1.6k 1.1×	756 0.7×	645 1.2×	1.6k 3.2×	264 0.6×	89	3.5k
Reingard Senekowitsch–Schmidtke Germany	31	2.3k 1.5×	826 0.8×	1.2k 2.3×	629 1.2×	572 1.3×	84	3.9k
W. Sauerwein Germany	31	1.8k 1.2×	547 0.5×	359 0.7×	768 1.5×	109 0.2×	204	3.7k
Dawen Zhao United States	33	923 0.6×	581 0.6×	1.3k 2.4×	490 1.0×	872 1.9×	73	3.5k
Pat Price United Kingdom	31	2.7k 1.8×	1.0k 1.0×	935 1.8×	1.3k 2.5×	1.0k 2.2×	111	4.8k

Countries citing papers authored by Serge K. Lyashchenko

Since Specialization

Citations

This map shows the geographic impact of Serge K. Lyashchenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge K. Lyashchenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge K. Lyashchenko more than expected).

Fields of papers citing papers by Serge K. Lyashchenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge K. Lyashchenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge K. Lyashchenko. The network helps show where Serge K. Lyashchenko may publish in the future.

Co-authorship network of co-authors of Serge K. Lyashchenko

This figure shows the co-authorship network connecting the top 25 collaborators of Serge K. Lyashchenko. A scholar is included among the top collaborators of Serge K. Lyashchenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge K. Lyashchenko. Serge K. Lyashchenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yeh, Randy, Fresia Pareja, Parnian Shobeiri, et al.. (2025). Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis. Journal of Nuclear Medicine. 66(6). 873–879. 1 indexed citations

Scott, Andrew M., Brian M. Zeglis, Suzanne E. Lapi, et al.. (2024). Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. The Lancet Oncology. 25(6). e250–e259. 20 indexed citations

Lyashchenko, Serge K., et al.. (2024). Good practices for 89Zr radiopharmaceutical production and quality control. EJNMMI Radiopharmacy and Chemistry. 9(1). 40–40. 12 indexed citations

Lumish, Melissa, Steven B. Maron, Viktoriya Paroder, et al.. (2022). Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using⁸⁹Zr-Trastuzumab PET: A Pilot Study. Journal of Nuclear Medicine. 64(5). 724–730. 14 indexed citations

Souweidane, Mark M., Kim Kramer, Sofia Haque, et al.. (2022). DIPG-53. Long-term survival from a Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic124I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG).. Neuro-Oncology. 24(Supplement_1). i30–i31. 2 indexed citations

Feldman, Darren R., Robert J. Motzer, Andrea Knežević, et al.. (2022). STARLITE 2: Phase 2 study of nivolumab plus ¹⁷⁷Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (¹⁷⁷Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 40(16_suppl). TPS4603–TPS4603. 6 indexed citations

Korde, Aruna, Renata Mikołajczak, Petra Kolenc Peitl, et al.. (2022). Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry. 7(1). 18–18. 20 indexed citations

Young, Robert J., Paula Demétrio De Souza França, Giacomo Pirovano, et al.. (2020). Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR. Neuro-Oncology Advances. 2(1). vdaa119–vdaa119. 26 indexed citations

Schöder, Heiko, Paula Demétrio De Souza França, Reiko Nakajima, et al.. (2020). Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. Clinical Cancer Research. 26(13). 3110–3116. 48 indexed citations

10.

Modak, Shakeel, Pat Zanzonico, Milan Grkovski, et al.. (2020). B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. Journal of Clinical Oncology. 38(36). 4283–4291. 53 indexed citations

11.

Ulaner, Gary A., Jorge A. Carrasquillo, Christopher C. Riedl, et al.. (2020). Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT. Radiology. 296(2). 370–378. 45 indexed citations

12.

Lohrmann, Christian, Eileen M. O’Reilly, Joseph A. O’Donoghue, et al.. (2019). Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. Clinical Cancer Research. 25(23). 7014–7023. 48 indexed citations

13.

Reidy‐Lagunes, Diane, Neeta Pandit‐Taskar, Joseph A. O’Donoghue, et al.. (2019). Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. Clinical Cancer Research. 25(23). 6939–6947. 71 indexed citations

14.

Sharma, Sai Kiran, Serge K. Lyashchenko, Nagavarakishore Pillarsetty, et al.. (2019). A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nuclear Medicine and Biology. 71. 32–38. 37 indexed citations

15.

Miloushev, Vesselin Z., Kristin L. Granlund, Rostislav Boltyanskiy, et al.. (2018). Metabolic Imaging of the Human Brain with Hyperpolarized 13C Pyruvate Demonstrates 13C Lactate Production in Brain Tumor Patients. Cancer Research. 78(14). 3755–3760. 176 indexed citations

16.

Ulaner, Gary A., Serge K. Lyashchenko, Christopher C. Riedl, et al.. (2017). First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. Journal of Nuclear Medicine. 59(6). 900–906. 141 indexed citations

17.

Ulaner, Gary A., David M. Hyman, Serge K. Lyashchenko, Jason S. Lewis, & Jorge A. Carrasquillo. (2017). 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2–Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer. Clinical Nuclear Medicine. 42(12). 912–917. 101 indexed citations

18.

Pandit‐Taskar, Neeta, Pat Zanzonico, Kevin D. Staton, et al.. (2017). Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. Journal of Nuclear Medicine. 59(1). 147–153. 86 indexed citations

19.

Ulaner, Gary A., David M. Hyman, Dara S. Ross, et al.. (2016). Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹Zr-Trastuzumab PET/CT. Journal of Nuclear Medicine. 57(10). 1523–1528. 144 indexed citations

20.

Beylergil, Volkan, Patrick G. Morris, Peter Smith‐Jones, et al.. (2013). Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications. 34(12). 1157–1165. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact